Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops ...

Older adults with HIV are at significantly higher risk for cutaneous malignancies when compared with younger patients with HIV.

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.